\
&
Contact us
\
&
Contact us
Published on | 2 years ago
Programmes Horizon Europe Digital EuropeThe threats to cybersecurity increase continuously, affecting all systems managing data and information that might be interesting for intruders. The Funding & Tenders (F&T) Portal hosts a wealth of interesting information that might be under threat if users do not take the necessary measures.
Therefore the European Commission decided in Q4-2022 to increase the security and stimulate users to switch to using two-factor authentication (instead of the simple user name – password). A log-in as user is required in the F&T portal when you want to register as an organisation or to enter into the management of your proposal/project.
This switch to two-factor authentication requires limited effort. You have to register a mobile device, app or USB security key and activate the two-factor authentication. At each login, you will then be prompted for your usual password and for a second factor that is sent to your phone, app or you'll have to enter your USB key. A short video guides you through the installation. There also is an FAQ page available.
Currently two-factor authorisation is used by less than 1% of the users, but it is a priority for the EC to increase the usage level. On a practical note: if you are planning on switching to a new phone in the near future (e.g. before summer), we would advise you to wait until then to activate the 2 factor authentication. In any other case, there is no reason to postpone the activation of the extra verification step.
This is a revised version of a news item that was originally published on 2022-11-17.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Research Infrastructures Horizon Europe Digital Europe
Building on the revised Charter for access to research infrastructures , this new Charter will be specifically aimed at facilitating access of companies. It will make it easier for companies, especially small and medium-sized businesses (SMEs), startups and scaleups, to access Europe’s world-class research and technology... read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
